Harpoon Therapeutics (HARP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Harpoon Therapeutics (HARP) trades at $23.01 with AI Score 61/100 (Grade B+). Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company focused on developing T cell engagers for cancer treatment. Market cap: $865.08M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for HARP: HARP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HARP against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HARP: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Harpoon Therapeutics (HARP) Healthcare & Pipeline Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, is pioneering TriTAC-based T cell engagers to treat various cancers. With a focus on harnessing the body's immune system, Harpoon is advancing clinical trials for HPN328, HPN217, and HPN536, targeting solid tumors and hematologic malignancies, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for HARP?
Harpoon Therapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative TriTAC platform and promising clinical pipeline. The company's focus on T cell engagers offers a novel approach to cancer immunotherapy, potentially addressing unmet needs in various tumor types. Key value drivers include the advancement of HPN328, HPN217, and HPN536 through clinical trials, with potential data readouts serving as significant catalysts. The collaboration with AbbVie provides financial validation and potential for future revenue streams. However, the company's negative profit margin of -210.4% and reliance on clinical trial success pose significant risks. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the long-term viability of Harpoon's technology and market potential.
Based on FMP financials and quantitative analysis
HARP Key Highlights
- Market capitalization of $865.08M reflects investor confidence in Harpoon's TriTAC platform and clinical pipeline.
- Gross margin of 90.3% indicates strong potential profitability upon successful commercialization of its product candidates.
- Profit margin of -210.4% highlights the company's current reliance on R&D spending and lack of product revenue.
- HPN328 is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors.
- Collaboration with AbbVie Biotechnology Ltd. provides financial support and validation of Harpoon's TriTAC technology.
Who Are HARP's Competitors?
HARP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| XNCR Xencor, Inc. | $15.00 | +0.02% | $1.11B | — |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| NKTR Nektar Therapeutics | $71.62 | +0.82% | $1.40B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HARP's Key Strengths?
- Novel TriTAC platform technology.
- Promising clinical pipeline.
- Strategic collaboration with AbbVie.
- Experienced management team.
What Are HARP's Weaknesses?
- Clinical-stage company with no approved products.
- High R&D expenses.
- Reliance on clinical trial success.
- Negative profit margin.
What Could Drive HARP Stock Higher?
- Data readouts from Phase I/II clinical trials of HPN328 for small cell lung cancer.
- Data readouts from Phase I/II clinical trials of HPN217 for multiple myeloma.
- Data readouts from Phase I/IIa clinical trials of HPN536 for ovarian and pancreatic cancer.
- Continued enrollment and progress in ongoing clinical trials.
- Potential for new strategic partnerships and collaborations.
What Are the Key Risks for HARP?
- Financial-distress signal — its Altman Z-Score of 0.36 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from other immunotherapy companies.
- High R&D expenses and reliance on external funding.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for HARP?
- Expansion into New Therapeutic Areas: Harpoon has the opportunity to expand its TriTAC platform into new therapeutic areas beyond oncology, such as autoimmune diseases and infectious diseases. The market for autoimmune disease therapies is substantial, with a global market size projected to reach billions of dollars by 2030. By leveraging its T cell engager technology, Harpoon could address unmet needs in these areas and diversify its revenue streams. This expansion would require further research and development efforts and strategic partnerships.
- Advancement of HPN601: The preclinical stage product HPN601 represents a significant growth opportunity for Harpoon. Targeting multiple solid tumor indications, HPN601 has the potential to address a broad patient population. Successful preclinical development and subsequent clinical trials could lead to a valuable addition to Harpoon's pipeline. The timeline for HPN601's development will depend on preclinical data and regulatory approvals, with potential clinical trials commencing within the next 2-3 years.
- Strategic Partnerships and Collaborations: Harpoon can pursue additional strategic partnerships and collaborations with pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide financial resources, expertise, and access to new markets. The collaboration with AbbVie serves as a model for future partnerships, potentially leading to co-development agreements and revenue sharing opportunities. Securing such partnerships will be crucial for Harpoon's long-term growth and success.
- Geographic Expansion: Harpoon can expand its geographic reach beyond the United States by pursuing regulatory approvals and commercialization in international markets. The European Union and Asia-Pacific regions represent significant growth opportunities for cancer immunotherapy products. Expanding into these markets would require establishing local partnerships, conducting clinical trials in relevant populations, and navigating regulatory pathways. This expansion could significantly increase Harpoon's revenue potential and market share.
- Combination Therapies: Harpoon can explore the potential of combining its TriTAC-based T cell engagers with other cancer therapies, such as checkpoint inhibitors and chemotherapy. Combination therapies may offer synergistic effects and improve patient outcomes. Clinical trials evaluating these combinations could demonstrate the added value of Harpoon's products and expand their market potential. The timeline for these trials will depend on preclinical data and regulatory approvals, with potential studies commencing within the next 1-2 years.
What Opportunities Does HARP Have?
- Expansion into new therapeutic areas.
- Advancement of HPN601.
- Strategic partnerships and collaborations.
- Geographic expansion.
What Threats Does HARP Face?
- Competition from other immunotherapy companies.
- Regulatory hurdles.
- Clinical trial failures.
- Patent challenges.
What Are HARP's Competitive Advantages?
- Proprietary TriTAC platform technology.
- Strong intellectual property portfolio.
- Clinical trial data demonstrating efficacy and safety.
- Strategic partnerships with leading pharmaceutical companies.
What Does HARP Do?
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to developing a novel class of T cell engagers. Founded in 2015 and headquartered in South San Francisco, California, the company's core technology, the Tri-specific T cell activating construct (TriTAC) platform, is designed to harness the power of the body's immune system to treat patients suffering from cancer and other diseases. Harpoon's lead product candidates include HPN328, currently in Phase I/II clinical trials for small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, also in Phase I/II clinical trials for multiple myeloma; and HPN536, in Phase I/IIa clinical trials for ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Additionally, the company has a preclinical stage product, HPN601, targeting multiple solid tumor indications. Harpoon has established a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating its TriTAC platform technology together with soluble T cell receptors, further validating its technology and expanding its reach in the immunotherapy space. Harpoon's focus on innovative T cell engager technology positions it as a key player in the evolving cancer treatment landscape.
What Products and Services Does HARP Offer?
- Develops tri-specific T cell activating construct (TriTAC) product candidates.
- Focuses on harnessing the body's immune system to treat cancer.
- Conducts Phase I/II clinical trials for HPN328 in small cell lung cancer.
- Conducts Phase I/II clinical trials for HPN217 in multiple myeloma.
- Conducts Phase I/IIa clinical trials for HPN536 in ovarian and pancreatic cancer.
- Develops preclinical stage product HPN601 for multiple solid tumor indications.
- Collaborates with AbbVie Biotechnology Ltd. to develop and commercialize products.
How Does HARP Make Money?
- Develops and patents novel T cell engager technology.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approvals from the FDA and other regulatory agencies.
- Partners with pharmaceutical companies for commercialization and distribution.
What Industry Does HARP Operate In?
Harpoon Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the cancer immunotherapy market. The industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The global cancer immunotherapy market is projected to reach significant growth in the coming years, driven by advancements in T cell therapies and personalized medicine. Harpoon's TriTAC platform positions it to compete with other immunotherapy companies, including those developing CAR-T cell therapies and checkpoint inhibitors. The company's success will depend on its ability to demonstrate clinical efficacy and safety, secure regulatory approvals, and establish strategic partnerships.
Who Are HARP's Key Customers?
- Patients suffering from cancer and other diseases.
- Oncologists and other healthcare professionals.
- Pharmaceutical companies seeking to develop and commercialize new cancer therapies.
F-Score 2/9Financial Health
Harpoon Therapeutics's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.36 places it in the distress zone, a signal of elevated financial risk.
HARP Valuation & Market Position
With a $865.08M market cap, Harpoon Therapeutics sits in the small-cap segment of the market. Relative to its peer group, HARP's quantitative score of 61/100 is roughly in line with the peer average of 70/100.
Key Financial Metrics
Return on assets is -91.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -88.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Harpoon Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Julie M. Eastland. HARP has traded publicly since 2019.
HARP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel TriTAC platform technology.
- Promising clinical pipeline.
- Strategic collaboration with AbbVie.
- Experienced management team.
Bear Case
- Clinical-stage company with no approved products.
- High R&D expenses.
- Reliance on clinical trial success.
- Negative profit margin.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HARP Latest News
-
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
benzinga · Oct 30, 2023
-
Stocks That Hit 52-Week Lows On Friday
benzinga · May 6, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Apr 27, 2022
HARP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HARP.
Price Targets
Wall Street price target analysis for HARP.
HARP MoonshotScore
What does this score mean?
The MoonshotScore rates HARP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Julie M. Eastland
Chief Executive Officer
Julie M. Eastland serves as the Chief Executive Officer of Harpoon Therapeutics, bringing extensive experience in the biotechnology industry. Her background includes leadership roles in various pharmaceutical and biotech companies, where she focused on strategic planning, business development, and commercialization. Eastland's expertise spans across multiple therapeutic areas, including oncology and immunology. She has a proven track record of driving growth and innovation in the biopharmaceutical sector.
Track Record: Since assuming the role of CEO, Julie M. Eastland has overseen the advancement of Harpoon's clinical pipeline, including the progression of HPN328, HPN217, and HPN536 through clinical trials. She has also been instrumental in securing strategic partnerships, such as the collaboration with AbbVie, which has provided financial support and validation for Harpoon's TriTAC technology. Under her leadership, Harpoon has focused on expanding its research and development efforts and strengthening its intellectual property portfolio.
What Investors Ask About Harpoon Therapeutics (HARP) — Healthcare
What does Harpoon Therapeutics, Inc. do?
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company focused on developing a novel class of T cell engagers using its proprietary TriTAC platform. These T cell engagers are designed to harness the body's immune system to target and eliminate cancer cells. The company's pipeline includes product candidates targeting various solid tumors and hematologic malignancies, with several programs currently in Phase I/II clinical trials. Harpoon's business model revolves around developing and commercializing these innovative immunotherapies, either independently or through strategic partnerships.
What do analysts say about HARP stock?
Analyst coverage of Harpoon Therapeutics (HARP) typically focuses on the potential of its TriTAC platform and the progress of its clinical pipeline. Key valuation metrics include the company's market capitalization, cash runway, and potential revenue from future product sales. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization efforts. Analyst consensus generally reflects cautious optimism, acknowledging the inherent risks associated with clinical-stage biotechnology companies but also recognizing the potential upside of Harpoon's innovative technology.
What are the main risks for HARP?
The main risks for Harpoon Therapeutics include the inherent uncertainties of clinical development, particularly the risk of clinical trial failures or delays. Regulatory hurdles and the potential for delays in obtaining approvals also pose significant risks. Competition from other immunotherapy companies, including those developing CAR-T cell therapies and checkpoint inhibitors, could limit Harpoon's market share. Additionally, the company faces financial risks associated with high R&D expenses and reliance on external funding, as well as potential patent challenges and intellectual property disputes.
What are the key factors to evaluate for HARP?
Harpoon Therapeutics (HARP) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does HARP data refresh on this page?
HARP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HARP's recent stock price performance?
Harpoon Therapeutics (HARP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel TriTAC platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HARP overvalued or undervalued right now?
Valuing Harpoon Therapeutics (HARP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HARP?
Before investing in Harpoon Therapeutics (HARP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Clinical trial outcomes are inherently uncertain and may impact the company's future prospects.